These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

582 related items for PubMed ID: 26518722

  • 1. Targeting CD44 expressing cancer cells with anti-CD44 monoclonal antibody improves cellular uptake and antitumor efficacy of liposomal doxorubicin.
    Arabi L, Badiee A, Mosaffa F, Jaafari MR.
    J Control Release; 2015 Dec 28; 220(Pt A):275-286. PubMed ID: 26518722
    [Abstract] [Full Text] [Related]

  • 2. Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model.
    Zahmatkeshan M, Gheybi F, Rezayat SM, Jaafari MR.
    Eur J Pharm Sci; 2016 Apr 30; 86():125-35. PubMed ID: 26972276
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Extensive preclinical investigation of polymersomal formulation of doxorubicin versus Doxil-mimic formulation.
    Alibolandi M, Abnous K, Mohammadi M, Hadizadeh F, Sadeghi F, Taghavi S, Jaafari MR, Ramezani M.
    J Control Release; 2017 Oct 28; 264():228-236. PubMed ID: 28844758
    [Abstract] [Full Text] [Related]

  • 6. Formulation and optimization of idarubicin thermosensitive liposomes provides ultrafast triggered release at mild hyperthermia and improves tumor response.
    Lu T, Lokerse WJM, Seynhaeve ALB, Koning GA, Ten Hagen TLM.
    J Control Release; 2015 Dec 28; 220(Pt A):425-437. PubMed ID: 26541464
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Targeting the leptin receptor: To evaluate therapeutic efficacy and anti-tumor effects of Doxil, in vitro and in vivo in mice bearing C26 colon carcinoma tumor.
    Amiri Darban S, Nikoofal-Sahlabadi S, Amiri N, Kiamanesh N, Mehrabian A, Zendehbad B, Gholizadeh Z, Jaafari MR.
    Colloids Surf B Biointerfaces; 2018 Apr 01; 164():107-115. PubMed ID: 29413587
    [Abstract] [Full Text] [Related]

  • 10. Enhanced doxorubicin delivery to hepatocellular carcinoma cells via CD147 antibody-conjugated immunoliposomes.
    Wang J, Wu Z, Pan G, Ni J, Xie F, Jiang B, Wei L, Gao J, Zhou W.
    Nanomedicine; 2018 Aug 01; 14(6):1949-1961. PubMed ID: 29045824
    [Abstract] [Full Text] [Related]

  • 11. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model.
    Moosavian SA, Abnous K, Badiee A, Jaafari MR.
    Colloids Surf B Biointerfaces; 2016 Mar 01; 139():228-36. PubMed ID: 26722819
    [Abstract] [Full Text] [Related]

  • 12. Development of a novel cyclic RGD peptide for multiple targeting approaches of liposomes to tumor region.
    Amin M, Mansourian M, Koning GA, Badiee A, Jaafari MR, Ten Hagen TLM.
    J Control Release; 2015 Dec 28; 220(Pt A):308-315. PubMed ID: 26526970
    [Abstract] [Full Text] [Related]

  • 13. Effect of linker variation on the stability, potency, and efficacy of carcinoma-reactive BR64-doxorubicin immunoconjugates.
    Trail PA, Willner D, Knipe J, Henderson AJ, Lasch SJ, Zoeckler ME, TrailSmith MD, Doyle TW, King HD, Casazza AM, Braslawsky GR, Brown J, Hofstead SJ, Greenfield RS, Firestone RA, Mosure K, Kadow KF, Yang MB, Hellström KE, Hellström I.
    Cancer Res; 1997 Jan 01; 57(1):100-5. PubMed ID: 8988048
    [Abstract] [Full Text] [Related]

  • 14. Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models.
    Gabizon A, Tzemach D, Mak L, Bronstein M, Horowitz AT.
    J Drug Target; 2002 Nov 01; 10(7):539-48. PubMed ID: 12683721
    [Abstract] [Full Text] [Related]

  • 15. Doxil synergizes with cancer immunotherapies to enhance antitumor responses in syngeneic mouse models.
    Rios-Doria J, Durham N, Wetzel L, Rothstein R, Chesebrough J, Holoweckyj N, Zhao W, Leow CC, Hollingsworth R.
    Neoplasia; 2015 Aug 01; 17(8):661-70. PubMed ID: 26408258
    [Abstract] [Full Text] [Related]

  • 16. Investigation of Hexadecylphosphocholine (miltefosine) usage in Pegylated liposomal doxorubicin as a synergistic ingredient: In vitro and in vivo evaluation in mice bearing C26 colon carcinoma and B16F0 melanoma.
    Teymouri M, Farzaneh H, Badiee A, Golmohammadzadeh S, Sadri K, Jaafari MR.
    Eur J Pharm Sci; 2015 Dec 01; 80():66-73. PubMed ID: 26299343
    [Abstract] [Full Text] [Related]

  • 17. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.
    Gabizon A, Tzemach D, Gorin J, Mak L, Amitay Y, Shmeeda H, Zalipsky S.
    Cancer Chemother Pharmacol; 2010 May 01; 66(1):43-52. PubMed ID: 19779718
    [Abstract] [Full Text] [Related]

  • 18. A simple way to enhance Doxil® therapy: drug release from liposomes at the tumor site by amphiphilic block copolymer.
    Zhao Y, Alakhova DY, Kim JO, Bronich TK, Kabanov AV.
    J Control Release; 2013 May 28; 168(1):61-9. PubMed ID: 23474033
    [Abstract] [Full Text] [Related]

  • 19. Local targeted therapy of liver metastasis from colon cancer by galactosylated liposome encapsulated with doxorubicin.
    Zhao C, Feng Q, Dou Z, Yuan W, Sui C, Zhang X, Xia G, Sun H, Ma J.
    PLoS One; 2013 May 28; 8(9):e73860. PubMed ID: 24040096
    [Abstract] [Full Text] [Related]

  • 20. Tumor-targeted nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody.
    ElBayoumi TA, Torchilin VP.
    Clin Cancer Res; 2009 Mar 15; 15(6):1973-80. PubMed ID: 19276264
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.